227 related articles for article (PubMed ID: 24682604)
1. Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis.
Fujimoto D; Ueda H; Shimizu R; Kato R; Otoshi T; Kawamura T; Tamai K; Shibata Y; Matsumoto T; Nagata K; Otsuka K; Nakagawa A; Otsuka K; Katakami N; Tomii K
Clin Exp Metastasis; 2014 Jun; 31(5):543-51. PubMed ID: 24682604
[TBL] [Abstract][Full Text] [Related]
2. The features and prognostic impact of extracranial metastases in patients with epidermal growth factor receptor-mutant lung adenocarcinoma.
Bi J; Han G; Wei X; Pi G; Zhang Y; Li Y; Wang M; Hu D; Zhen W
J Cancer Res Ther; 2018; 14(4):799-806. PubMed ID: 29970656
[TBL] [Abstract][Full Text] [Related]
3. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
4. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
5. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score.
Lee DW; Shin DY; Kim JW; Keam B; Kim TM; Kim HJ; Kim DW; Wu HG; Paek SH; Kim YW; Heo DS; Kim DG; Lee SH
Lung Cancer; 2014 Dec; 86(3):363-8. PubMed ID: 25453849
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
[TBL] [Abstract][Full Text] [Related]
7. Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis.
Kim M; Suh CH; Lee SM; Park JE; Kim HC; Kim SO; Aizer AA; Yanagihara TK; Bai HX; Guenette JP; Huang RY; Kim HS
AJR Am J Roentgenol; 2021 Nov; 217(5):1184-1193. PubMed ID: 34037408
[No Abstract] [Full Text] [Related]
8. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
9. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.
Chen Y; Yang J; Li X; Hao D; Wu X; Yang Y; He C; Wang W; Wang J
Cancer Sci; 2016 Dec; 107(12):1800-1805. PubMed ID: 27627582
[TBL] [Abstract][Full Text] [Related]
10. EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma.
Tanaka K; Hida T; Oya Y; Oguri T; Yoshida T; Shimizu J; Horio Y; Hata A; Kaji R; Fujita S; Sekido Y; Kodaira T; Kokubo M; Katakami N; Yatabe Y
J Thorac Oncol; 2015 Dec; 10(12):1720-5. PubMed ID: 26743855
[TBL] [Abstract][Full Text] [Related]
11. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.
Lin JJ; Cardarella S; Lydon CA; Dahlberg SE; Jackman DM; Jänne PA; Johnson BE
J Thorac Oncol; 2016 Apr; 11(4):556-65. PubMed ID: 26724471
[TBL] [Abstract][Full Text] [Related]
12. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
[TBL] [Abstract][Full Text] [Related]
13. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.
Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K
Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080
[TBL] [Abstract][Full Text] [Related]
14. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients.
Hsiao SH; Lin HC; Chou YT; Lin SE; Kuo CC; Yu MC; Chung CL
Lung Cancer; 2013 Sep; 81(3):455-461. PubMed ID: 23871711
[TBL] [Abstract][Full Text] [Related]
15. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?
Han G; Bi J; Tan W; Wei X; Wang X; Ying X; Guo X; Zhou X; Hu D; Zhen W
Oncotarget; 2016 Aug; 7(35):56998-57010. PubMed ID: 27486770
[TBL] [Abstract][Full Text] [Related]
16. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
17. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients.
Yomo S; Oda K
Lung Cancer; 2018 May; 119():120-126. PubMed ID: 29656746
[TBL] [Abstract][Full Text] [Related]
18. Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China.
Li H; Cao J; Zhang X; Song X; Wang W; Jia S; Li Z; Jia H; Cao X; Zhou W; Lian J; Han S; Yang W; Xi Y; Lian S; Jing H
Clin Exp Metastasis; 2017 Jan; 34(1):63-71. PubMed ID: 27888377
[TBL] [Abstract][Full Text] [Related]
19. Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance.
Ohba T; Toyokawa G; Kometani T; Nosaki K; Hirai F; Yamaguchi M; Hamatake M; Seto T; Ichinose Y; Sugio K
Surg Today; 2014 Mar; 44(3):478-86. PubMed ID: 23609009
[TBL] [Abstract][Full Text] [Related]
20. Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma.
Dormieux A; Mezquita L; Cournede PH; Remon J; Tazdait M; Lacroix L; Rouleau E; Adam J; Bluthgen MV; Facchinetti F; Tselikas L; Aboubakar F; Naltet C; Lavaud P; Gazzah A; Le Pechoux C; Lassau N; Balleyguier C; Planchard D; Besse B; Caramella C
Eur Radiol; 2020 Sep; 30(9):5021-5028. PubMed ID: 32323012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
